FDA has granted Tessa Therapeutics investigational CD30-directed autologous chimeric antigen receptor T cell therapy Regenerative Medicine Advanced Therapy for relapsed or refractory CD30-positive classical Hodgkin lymphoma.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
